Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Myelodysplastic Syndrome.
Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Solid Tumor.
The predictive model demonstrated an 8-year cumulative incidence of TKI failure in the training set of 10% in the low-risk group, 34% in the intermediate risk, and 69% in the high-risk. In the ...
With a projected Compound Annual Growth Rate (CAGR) of $% during the forecast period (2022-2028), the US AML market is well-positioned for substantial progression, underpinned by the convergence of ...
Bone marrow transplants, long a mainstay of blood cancer treatments, are becoming less common in favor of options like CAR-T ...
This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...
Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.
Aster Aging cares for seniors in a variety of ways, including Meals on Wheels and activities. But it also fights loneliness ...
Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...
Mel Mann shares his inspiring 30-year journey with chronic myeloid leukemia, from a terminal diagnosis to long-term survival.
Alana Kent took to TikTok to list the signs of the condition - which she initially believed would soon resolve - with the ...
Mitochondria are pivotal cellular organelles that play a crucial role in regulating metabolism and cell survival, making them ...